Drreddys Laboratories | RDY - Cost Of Sales


Drreddys Laboratories reported INR32.13B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 119.8M 5.3M Jun/2026
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cipla INR 29.71B 3.4B Jun/2026
Corcept Therapeutics USD 4.06M 1.18M Jun/2026
Drreddys Laboratories INR 32.13B 8.34B Mar/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Novartis USD 3.71B 251M Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 135.22M 5.54M Jun/2026
Richter Gedeon HUF 72.45B 1.13B Mar/2026
Sun Pharmaceuticals INR 37.02B 9.01B Jun/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026
Teva Pharmaceutical Industries USD 1.98B 30M Jun/2026